MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$43.45 USD
+0.39 (0.91%)
Updated Aug 8, 2024 01:18 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for MoonLake Immunotherapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 54 | 65 | 5 | 0 | 0 |
Income After Depreciation & Amortization | -54 | -65 | -5 | 0 | 0 |
Non-Operating Income | 10 | 1 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -44 | -64 | -5 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | -8 | -15 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -44 | -65 | -5 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -36 | -50 | -5 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -54 | -65 | -5 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -54 | -65 | -5 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.12 | 29.36 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.73 | -1.70 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.73 | -1.70 | -0.31 | -0.04 | NA |
Fiscal Year end for MoonLake Immunotherapeutics falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.82 | 15.03 | 12.98 | 13.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -19.82 | -15.03 | -12.98 | -13.18 |
Non-Operating Income | NA | 5.92 | 7.19 | 1.39 | 0.84 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -13.91 | -7.84 | -11.59 | -12.34 |
Income Taxes | NA | 0.07 | 0.04 | 0.03 | 0.01 |
Minority Interest | NA | -0.30 | -2.56 | 0.00 | -2.30 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.98 | -7.89 | -11.62 | -12.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.67 | -5.33 | -11.62 | -10.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 62.64 | 59.92 | 53.52 | 43.72 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.12 | -0.18 | -0.23 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.09 | -0.18 | -0.23 |